The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus
Ram’s appointment follows the launch of the CDI India division in October 2021.
The drug is priced at Rs 2000 for a course of 40 tablets
It is the generic version of molnupiravir
The facility at the Andhra Pradesh Medtech Zone is expected to be completed by Dec 2022
DCGI approved the drug based on the review of clinical data
The drug will be marketed under the brand name Molnaflu
Trastuzumab is monoclonal antibody used to treat human epidermal growth factor receptor 2 positive (HER2+) breast cancer and metastatic gastric cancers
The study was performed independently by investigators at the US Food and Drug Administration (FDA), Center for Biologics Evaluation and Research
Immatics to receive upfront payment of US $ 150 million and additional milestone payments of up to US $ 770 million plus tiered double-digit royalties on net product sales
Subscribe To Our Newsletter & Stay Updated
